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Background:  40 
Clomiphene citrate (CC) is in many countries the treatment of first choice in women with 41 
normogonadotropic anovulation.  If these women ovulate but do not conceive after several cycles with 42 
CC, medication is usually switched to gonadotrophins, with or without intrauterine insemination (IUI). 43 
We aimed to assess whether switching to gonadotrophins is more effective than continuing CC, and 44 
whether IUI is more effective than intercourse. 45 
 46 
Methods: 47 
We performed a two-by-two factorial multicenter randomized clinical trial including women with 48 
normogonadotropic anovulation not pregnant after six ovulatory cycles with CC (NTR1449). Women 49 
were randomized using a central password protected internet-based randomization program to six 50 
cycles with gonadotrophins plus IUI, six cycles with gonadotrophins plus intercourse, six cycles with CC 51 
plus IUI or six cycles with CC plus intercourse. CC dosages varied from 50 to 150 mg daily orally and 52 
gonadotrophin starting dose was 50 or 75 IU daily subcutaneously. 53 
Primary outcome was conception leading to live birth within eight months after randomization. Primary 54 
analysis was by intention to treat. We made two comparisons, one in which gonadotrophins was 55 
compared to CC and one in which IUI was compared to intercourse. 56 
 57 
Findings: 58 
Between December 8th 2008 and December 16th 2015 we randomized 666 women to gonadotrophins/IUI 59 
(N=166), gonadotrophins/intercourse (N=165), CC/IUI (N=163), or CC/intercourse (N=172). 60 
Women allocated to gonadotrophins had more live births than those allocated to CC (167 of 327 women 61 





live births compared to intercourse (161 of 327 women [49·2%] vs. 144 of 334 [43·1%], RR 1·14 (95% CI 63 
0·97-1·35), p = 0·1152). 64 
Multiple pregnancy rates for the two comparisons were low and not different. 65 
There were three adverse events: one child with congenital abnormalities, one immature delivery due to 66 
cervical insufficiency, and one stillbirth. 67 
 68 
Interpretation: In women with normogonadotropic anovulation and CC failure, a switch of treatment to 69 
gonadotrophins increases chances of live birth over treatment with CC, while we could not prove that 70 
addition of IUI does so. 71 
 72 
Funding: This trial was funded by the Netherlands Organization for Health Research and Development. 73 
(80-82310-97-12067). 74 
 75 








Research in context panel 80 
Evidence before this study  81 
A comprehensive literature search using PubMed was done on September 15th 2008 before the trial 82 
started to identify all previous studies investigating women with clomiphene failure. Search terms 83 
included ‘’ovulation induction’’, ‘’polycystic ovary syndrome’’, ‘’clomiphene citrate’’ (CC), ‘’ 84 
gonadotrophins’’, and ‘’IUI’’. We only identified non-randomized studies indicating that continued 85 
treatment with CC and a treatment switch to gonadotrophins are both effective options for these women. 86 
If IUI increases pregnancy rates in women with CC failure is unknown. 87 
We wanted to investigate if, in women who have failed to conceive after six ovulatory cycles with CC, 88 
ovulation induction with gonadotrophins leads to more live birth rates than continued ovulation induction 89 
with CC and if IUI gives more live births than intercourse. 90 
 91 
Added value of this study  92 
The M-OVIN (Modified ovulation induction) study compared in anovulatory women with CC failure two 93 
types of medication as well as addition of IUI with intercourse. We found that a switch to gonadotrophins 94 
significantly increases the live birth rate as compared to continued treatment with CC and that the 95 
addition of IUI to gonadotrophins or CC seems not to increase live birth rates in women who are 96 
anovulatory. 97 
 98 
Implications of all the available evidence  99 
Our findings imply that, for normogonadotropic anovulatory women with CC failure who wish to conceive, 100 
continued treatment with CC or a treatment switch to gonadotrophins are both effective options in terms 101 
of live birth rates whereas we could not prove this for IUI. The choice between CC and gonadotrophins 102 
should be made based on women’s preferences, costs and, reimbursement. Considering recent 103 
randomized research suggesting that letrozole gives higher live birth rates than CC in the first six cycles, 104 
we suggest that future research establishes if continuing letrozole is also effective and safe if women 105 






Women with normogonadotropic anovulation have absent or irregular ovulation due to hypothalamic-108 
pituitary-ovarian dysfunction associated with normal levels of endogenous estradiol.1 In these women 109 
wishing to conceive, Clomiphene Citrate (CC) has long been used as a first-line ovulation induction 110 
agent.2,3 Systematic reviews and meta-analyses show that CC is an effective primary treatment option in 111 
therapy-naive women with normogonadotropic anovulation and polycystic ovary syndrome (PCOS).4-6 112 
Although ovulation is restored in ~75% of women starting ovulation induction with CC, six months of 113 
treatment leads to conception in only about half of these women.5,7 Women not conceiving after six 114 
ovulatory cycles are defined as having CC failure.8 The National Institute for Health and Care Excellence 115 
(NICE) guideline recommends not to extend treatment with CC for more than six cycles, but this 116 
recommendation is not underpinned by any evidence.9 In daily practice, these women usually switch to 117 
ovulation induction with gonadotrophins and intra-uterine insemination (IUI) is often initiated instead of 118 
relying on regular intercourse.10 However, the effectiveness of a switch to gonadotrophins and IUI 119 
compared to continued treatment with CC has never been studied in randomized clinical trials. 120 
We therefore conducted a randomized clinical trial to compare, in women who had six ovulatory cycles 121 
with CC but did not conceive, the effectiveness of a switch to gonadotrophins as compared to continued 122 







Study design 126 
The M-OVIN (Modified ovulation induction) study was a multicenter randomized clinical trial performed 127 
in 48 Dutch hospitals within the infrastructure of the Dutch Consortium for Healthcare Evaluation and 128 
Research in Obstetrics and Gynaecology (www.studies-obsgyn.nl).  129 
The study was granted approval by the Medical Ethical Committee of the Medical Spectrum Twente 130 
Enschede (The Netherlands) and from the Central Committee on Research involving Human Subjects 131 
(CCMO), The Netherlands (References P08-40 and Eudract number 2008-006171-73). The board of 132 
directors of each of the participating centers approved local execution of the study. 133 
The protocol was published previously11 and the study is registered in the Netherlands Trial Register 134 
(NTR1449). Two major adjustments to the protocol were made: The first, in April 2014, regarded a 135 
change in the primary outcome from ‘ongoing pregnancy’ to ‘live birth’. The second regarded the  136 
sample size which is specified in addendum 2. Both adjustments were approved by the Medical Ethical 137 
Committee.  138 
 139 
Randomization and masking 140 
Eligible women were informed about the study in or immediately after their sixth treatment cycle either 141 
by their doctor or by a dedicated research nurse. After written informed consent women were 142 
randomized using a central password protected internet-based randomization program. The 143 
randomization list had been prepared by an independent statistician with a variable block size with a 144 
maximum block size of 8. There was no masking. 145 
We used a two-by-two factorial design to compare two pairs of interventions: a switch to ovulation 146 





assigned to six cycles with gonadotrophins plus IUI, six cycles with gonadotrophins plus intercourse, six 148 
cycles with CC plus IUI, or six cycles with CC plus intercourse. 149 
 150 
Study population 151 
Subfertile women ≥ 18 years with WHO type II anovulation (menstrual cycle > 35 days, 152 
normogonadotropic, normo-oestrogenic, oligo-anovulation or anovulation), who had been ovulatory for 153 
six cycles on CC treatment, with a maximum of 150 mg daily for five days, but who had not conceived, 154 
were eligible for the trial. Presence of ovulation was assessed by a basal temperature curve, midluteal 155 
progesterone (> 16 nmol/l), detection of a urinary Luteinizing Hormone (LH) surge or transvaginal 156 
sonography, depending on the local protocol. All women had undergone a basic fertility work-up 157 
including a semen analysis and endocrinological screening to rule out hyperprolactinemia and 158 
uncorrected thyroid dysfunction. Couples with male subfertility could not participate. Women with 159 
abnormal prolactin (0·05-0·80 IU/l) or thyroid-stimulating hormone (0·4-4·0 mU/l) were also not eligible. 160 
Tubal pathology had to be ruled out by either a negative Chlamydia antibody titer (CAT) or 161 
hysterosalpingography, transvaginal hydrolaparoscopy, or diagnostic laparoscopy showing at least one 162 
patent Fallopian tube. Women with side effects in previous CC cycles were also not eligible. 163 
 164 
Interventions  165 
In women allocated to ovulation induction with gonadotrophins, a transvaginal ultrasound was usually 166 
performed on the third day of a menstrual bleeding and medication was started on that same day, but 167 
women were allowed to start medication up to day five . Treatment was not started if ultrasound 168 
showed ovarian cysts >25 mm in mean diameter. According to local protocol, urinary or recombinant 169 





monitored by transvaginal ultrasound and we aimed for mono-follicular growth. If  ≥ four dominant 171 
follicles (≥18  mm) developed, the cycle was cancelled i.e. couples were advised not to have intercourse 172 
and the planned IUI was not performed. When at least one follicle with a diameter of ≥ 16 mm was 173 
present, ovulation was triggered with 5.000 IU or 10.000 IU of human chorionic gonadotrophin (hCG). 174 
In women allocated to ovulation induction with CC started on the third to fifth day of a menstrual 175 
bleeding, in the same dosage as used in the last ovulatory cycle, varying between 50 mg and 150 mg 176 
daily, for five days. Ovulation was monitored by a basal temperature curve, midluteal progesterone (> 177 
16nmol/l), a urinary LH surge or transvaginal ultrasound, depending on the local protocol. The women 178 
undergoing ovulation induction with CC with IUI underwent monitoring by ultrasound, the other women 179 
were usually monitored by basal temperature curve, mid luteal progesterone measurement or urinary 180 
LH surge. In case of ovulation not followed by pregnancy, women continued taking the same dose of CC 181 
until pregnancy occurred, or until the end of the study eight months after randomization. If ovulation did 182 
not occur, the dosage was increased in increments of 50 mg to maximum of 150 mg daily in the next 183 
cycles.  184 
In couples allocated to IUI, semen samples were processed within one hour of ejaculation according to 185 
the local protocol and women were inseminated 36 to 40 hours after hCG injection. IUI was performed 186 
once per cycle. 187 
 188 
Follow up 189 
Follow-up started at the day of randomization and ended on the first day of the last menstruation before 190 
a positive pregnancy test within six treatment cycles or at eight months after randomization, whatever 191 





followed to delivery of their baby. If they miscarried or had an ectopic pregnancy within eight months 193 
after randomization, couples were advised to continue their allocated treatment. 194 
Data were collected by  trained research nurses and doctors. They used a structured case record form 195 
(CRF) to register the actual interventions, the reproductive outcomes, the occurrence of gestational 196 
diabetes, hypertensive disorders, stillbirths, preterm labour, and fetal birth weight as well as the course 197 
and outcome of subsequent pregnancies. If the women’s medical records did not suffice in giving the 198 
necessary information, women were contacted by telephone to ask about their outcomes. 199 
 200 
Withdrawal of individual patients 201 
We expected not all couples to complete the eight months of treatment as drop-outs represent normal 202 
patient flow, particularly in this protocol in which they already had six ovulatory treatment cycles before 203 
inclusion. Women who dropped out of the study were managed according to their preferences. 204 
 205 
Outcome measures 206 
The primary outcome measure was conception leading to live birth within eight months after 207 
randomization defined as any baby born alive after a gestational age beyond 24 weeks. Secondary 208 
outcome measures were ongoing pregnancy, multiple pregnancy, miscarriage (defined as loss of an 209 
intrauterine pregnancy confirmed by ultrasound or histological examination before the 20th week of 210 
pregnancy), ectopic pregnancy, time from randomization to the birth of a live child, fetal birth weight 211 
and pregnancy complications i.e. hypertensive disorders, gestational diabetes and preterm labour.11 We 212 





We do not report on all outcomes mentioned in the statistical analysis plan (addendum 3) here. 214 
Outcomes like clinical pregnancy rate, ovulation rate and gestational age will be reported elsewhere.  215 
 216 
Sample size calculation 217 
When we first planned our study, we designed the trial as a two-by-two2 factorial superiority trial. After 218 
recruiting 136 women, we received governmental funding that allowed enlargement of our trial. To 219 
evaluate if either switching to ovulation induction with gonadotrophins or addition of IUI would increase 220 
the live birth rate from 40% to 55%,12,13 we needed to include 600 women (alpha of 5% and a power of 221 
88% at three degrees of freedom). We decided to include a total of 660 women since 10% of women 222 
became pregnant after randomization but before starting the trial. With these 660 women we would 223 
have sufficient power to find a difference in live birth rate for the two comparisons that we have made. 224 
A detailed description of all steps in establishing the sample size is provided in addendum 2. A statistical 225 
analysis plan (addendum 3) was established prior to data lock. 226 
 227 
Statistical analysis 228 
The primary analysis was on an intention to treat basis. For the live birth rates and other binary outcome 229 
measures, we calculated absolute risks, relative risks and 95% confidence intervals. Chi-square test 230 
statistics were used to assess statistical significance.  231 
We reported categorical data as absolute numbers and percentages. We summarized normally 232 





continuous variables as medians with interquartile ranges. We formally tested for interaction between 234 
the two comparisons. 235 
 236 
We constructed Kaplan-Meier curves for time to conception leading to live birth for gonadotrophins 237 
versus CC, for IUI versus intercourse and for all four treatment arms separately. They were compared 238 
with a log-rank test. Two-sided P values of less than 0.05 were considered to indicate statistical 239 
significance. 240 
We assessed whether there was interaction between treatment effect and Body Mass Index (BMI) at cut-241 
off at 25kg/m2 as this was the mean BMI of our population. 242 
We also performed a per protocol analysis in which we only included women that were treated 243 
according to the predefined protocol. SPSS software (version 23.0; IBM Corp., USA) was used for 244 
statistical analysis. 245 
 246 
Study oversight and role of the funding source 247 
This trial was partially funded by the Netherlands Organization for Health Research and Development 248 
(ZonMw). (Health Care Efficiency Research; projectnumber : 80-82310-97-12067). The funder had no 249 
involvement in data collection, analysis or interpretation, and had no role in the writing of this 250 
manuscript or the decision to submit for publication. The corresponding author confirms to have had full 251 
access to all the data in the study and had final responsibility for the decision to submit for publication. 252 
 253 
RESULTS 254 
Between December 8th 2008 and December 16th 2015, we randomized 666 women. 166 women were 255 
allocated to ovulation induction with gonadotrophins combined with IUI, 165 to ovulation induction with 256 





induction with CC (Fig I). We excluded five women from analysis since they were randomized despite not 258 
fulfilling the inclusion criteria. None of these women became pregnant. The baseline characteristics were 259 
comparable across the four groups (Table I).  260 
Women allocated to gonadotrophins with IUI underwent 540 cycles, women allocated to gonadotrophins 261 
underwent 570 cycles, women allocated to CC with IUI underwent 612 cycles and women allocated to CC 262 
underwent 681 cycles. Of these cycles respectively 65 (12%) and 61 (11%) were cancelled in the 263 
gonadotrophins with IUI and gonadotrophins only arm. Of these cancelled cycles 35 (28%) were due to 264 
anovulation, the other cycles were cancelled because of multiple follicular growth. (Table II).  265 
 266 
Outcomes 267 
Women allocated to gonadotrophins had significantly more live births than women allocated to CC (167 268 
of 327 women [51·5%] vs. 138 of 334 [41·3%], (RR 1·24 (95% CI 1·05-1·46), p = 0·0124), absolute 269 
difference 10·2% (95% CI 2·4-17·9) Table III)). The mean time to conception leading to a live birth was 5 270 
months (95% CI 4·7-5·4) following gonadotrophins and 5·5 months (95% CI 5·1-5·8) following CC (log rank 271 
test, p=0·028, Fig II)). There were seven women (2%) allocated to gonadotrophins who conceived a twin 272 
pregnancy versus eight women (2%) allocated to CC (RR 0·89 (95% CI 0·33-2·4), p = 0.8262), absolute 273 
difference 0%).           274 
Women allocated to IUI had more live births than women allocated to intercourse, but this difference 275 
was not statistically different (161 of 327 women [49·2%] vs. 144 of 334 [43·1%], RR 1·14 (95% CI 0·97-276 
1·35), p = 0·1152), absolute difference 6·1% (95% CI -1·71 - 13·8) Table III). The mean time to conception 277 
leading to a live birth was 5·2 months (95% CI 4·8-5·5) with IUI and 5·3 months (95% CI 5·0-5·7) with 278 
intercourse (log rank test, p=0·27) Fig II)).There were 11 twin pregnancies after IUI (3%) and four after 279 
intercourse (1%) (RR 2·8 (95% CI 0·90-8·7), p = 0·0743), absolute difference 2·0%). There were no high 280 





The number of miscarriages was higher after treatment with gonadotrophins (n=24, 7%) than after CC 282 
(n=11, 3%) (RR 2·2 (95% CI 1·11-4·5), p = 0·0243), absolute difference 4·0%). Ectopic pregnancies were 283 
comparable between all groups. We found no differences in mean birth weights and pregnancy 284 
complications (Table III). 285 
No interaction was seen between the two comparisons (p = 0·932).  Also, there was no interaction of 286 
BMI and treatment effect for both comparisons.  287 
 288 
We included 563 women in the per protocol analysis. We found more live births after gonadotrophins 289 
compared to CC: 123/279 women (44·1%) after gonadotrophins versus 90/284 (31·6%) after CC (RR 1·38 290 
(95% CI 1·11-1·72), p = 0·0027), absolute difference 12·5%). Addition of IUI did not increase live births 291 
compared to intercourse: 113/277 women (40·8%) after IUI versus 100/286 (35·0%) women after 292 
intercourse (RR 1·17 (95% CI 0·94-1·44), p = 0·1548), absolute difference 12·5%). 293 
 294 
There were three adverse events: one woman treated with CC conceived a child with congenital 295 
abnormalities resulting in second trimester pregnancy termination, one woman treated with 296 
gonadotrophins with IUI delivered at a gestational age of 20 weeks due to cervical insufficiency, and one 297 






Table I. Baseline characteristics of the participating couples* 300 
 Gonadotrophins + IUI 
n = 164 
Gonadotrophins  
n =  163 
CC + IUI 
n = 163 
CC 
n = 171 
Mean female age (years)  
 
29·5 ± 3·7 29·9 ± 3·7 30·0 ± 3·6 29·9 ± 4·0 
Ethnicity 
   Caucasian 




24   (15) 
 
134 (88) 
18   (12) 
 
133 (86) 
21   (14) 
 
141 (89) 
18   (11) 
Mean BMI **  
   BMI >25.0  
 
25·4 ± 5·1 
76 (46) 
25·6 ± 5·6 
81 (49) 
25·0 ± 4·9 
64 (39) 
25·4 ± 5·0 
81 (47) 












1 1 3 2 
Previous live birth 
 
32 (20) 35 (21) 36 (22) 34 (20) 
Mean duration of subfertility (months) 
 
26·3 ± 14·9 24·5 ± 12·5 24·5 ± 15·5 25·9 ± 19·0 
Cycle pattern prior to treatment # 
  Amenorrhea 
  Oligomenorrhea 



















Median TMC *106 
 
52 (20-106) 43 (16-113) 53 (15-132) 38 (16-99) 










Mean serum biochemical values 
   FSH (IU/L) 
   LH (IU/L) 
   Estrogen (pmol/L) 
   Total testosterone (nmol/L) 
 
 
5·7 ± 2·1 
9·7 ± 7·4 
255 ± 295 
1·6 ± 1·7 
 
 
5·7 ± 1·7 
10·6 ± 7·8 
239 ± 217 
1·6 ± 2·0 
 
 
6·2 ± 2·2 
10·6 ± 7·6 
201 ± 159 
1·8 ± 2·2 
 
 
6·0 ± 2·2 
10·9 ± 10·8 
271 ± 460 
1·8 ± 1·8 
 
* Data are n (%), mean (SD) or median (IQR). There were no significant differences (P<0.05) between the four groups in any of 301 
the baseline characteristics. 302 
**BMI = the body-mass index which is the weight in kilograms divided by the square of height in meter. BMI was missing for 24 303 
women; data were imputed by using multiple imputation. 304 
# amenorrhea: absence of menstrual bleeding for >6 months. Oligomenorrhea: irregular menstrual bleedings with intervals 305 
of >35 days but ≤6 months 306 
## Defined as the presence of 12 or more follicles in each ovary measuring 2–9 mm in diameter 307 
IUI = intrauterine insemination 308 
CC = clomiphene citrate 309 
CAT = chlamydia antibody test 310 
TMC = total motile sperm count 311 
FSH = follicle stimulating hormone 312 
LH = luteinizing hormone 313 








FSH = Follicle stimulating hormone = gonadotrophins 318 
CC = clomiphene citrate 319 
IUI = intrauterine insemination 320 
*2 women had thyroid disease, 1 woman had bilateral tubal pathology, 1 male partner had azoospermia, 1 woman only had 2 321 
cycles with CC before randomization 322 
 323 
Table II. Cycle results* 324 








Total nr of cycles 540 570 612 681 
Mean nr of cycles per woman 3·3 ± 2·0 3·5 ± 2·1 3·8 ± 1·8 4·0 ± 1·9 
Mean nr of IUIs per woman 3·2 ± 2·2 0·04 ± 0·3 3·5 ± 2·2 0·05 ± 0·4  
Total nr of cancelled cycles 65 (12) 61 (11) 4** 2** 
Total units of gonadotrophins per 
woman 
2594 ± 2439 2640 ± 2577 153 ± 823** 223 ± 823** 
Total mg of CC per woman 4·5 ± 43·4 # 18·2 ± 128 # 1401 ± 1152 1255 ± 1139 
* Data are n (%) or mean (SD) 325 
**After switching to gonadotrophins 326 
# After switching to CC 327 
CC = clomiphene citrate 328 







Table III. Primary and secondary outcomes*  332 
 Gonadotrophins 
+ IUI 
n = 164 
Gonadotrophins  
 
n =  163 
CC + IUI 
 
n = 163 
CC 
 
n = 171 
Gonadotrophins 
vs CC 





vs i  






89 (54·3) 78 (47·9) 72 (44·2) 66 (38·6) 1·24 (1·05-1·46) 0·0124 1·1    
Ongoing pregnancy 
 
90 (54·9) 80 (49·1) 72 (44·2) 66 (38·6) 1·26 (1·07-1·48) 0·0063 1·1                            
Multiple pregnancy** per 
woman 
4 (2·4) 3 (1·8) 7 (4·3) 1 (0·6) 0·89 (0·33-2·4)            0·82 2·8   
Miscarriages per woman 
 
15 (9·1) 9 (5·5) 8 (4·9) 3 (1·8) 2·2 (1·11-4·5) 0·02 1·9    
Ectopic pregnancy per woman 
 
1 (0·6) 1 (0·6) 3 (1·8) 1 (0·6) #  #  
Mean birth weight (g) 
 
3279 ± 695 3302 ± 769 3178 ± 714 3408 ± 491  0·96   
Pregnancy complications 
• Hypertensive disorders 
• Gestational diabetes 






















 #  
*Data are n (%) or mean ± SD 333 
** All multiple pregnancies were twin pregnancies 334 
# No RR was calculated as the proportions are low. 335 
IUI Intrauterine insemination 336 
CC clomiphene citrate 337 
 338 
Figure II. Time to conception leading to live birth for the comparison gonadotrophins versus CC, and IUI versus intercourse 339 






DISCUSSION   342 
In this multicenter randomized trial, we found that, among normogonadotropic anovulatory women not 343 
pregnant after six ovulatory cycles with CC, a switch to gonadotrophins with strict cycle monitoring 344 
increased the live birth rate as compared to continued treatment with CC, while we could not prove this 345 
for the addition of IUI. All four treatment arms resulted in acceptable pregnancy rates and low 346 
complication rates. 347 
A strength of our study is the two-by-two factorial design. This design allowed us to dissect the effect of 348 
gonadotrophins and CC and to establish that IUI does not increases the chances of pregnancy compared 349 
to intercourse, although there was a tendency towards higher live birth rates after the fourth IUI-cycle. 350 
The per protocol analysis limited to women that received the allocated treatment did not alter these 351 
results suggesting that the treatment switches did not have a large effect on live birth chances. A 352 
weakness may be that we allowed participating hospitals to use their local protocols for ovulation 353 
induction and IUI. On the other hand, this pragmatic approach might increase the generalizability of the 354 
results. Plausible biological explanations for the finding of gonadotrophins giving more live births than CC 355 
may be the following. First, treatment with gonadotrophins requires strict cycle monitoring whereas 356 
treatment with CC does not. Therefore, women treated with gonadotrophins have more specific 357 
knowledge on the timing of their ovulation which may lead to a better timing of their intercourse. 358 
Second, CC is supposed to have negative effects on the endometrium, but studies examining this effect 359 
in relation to pregnancy rates show conflicting results 14-16. Third, CC possibly induces cervical factor 360 
subfertility by influencing the cervical mucus.17-19  361 
We do not know whether the differential monitoring in the women that underwent ovulation induction 362 
with CC has had impact on the outcomes, but it is not something we expect. The addition of IUI where 363 





the merits of our study is that even with minimal monitoring good results can be obtained with 365 
continued ovulation induction with CC. 366 
We found a small, not statistically significant effect of IUI on live birth rates which seemed to increase 367 
after cycle four.  Apparently, IUI does not contribute to pregnancy chances in women with anovulatory 368 
subfertility but, once the ovulation disorder has been resolved by either gonadotropins or CC and 369 
conception does not occur, IUI may make a difference. These women could be considered to have 370 
unexplained subfertility in whom IUI is standard treatment.  371 
We found  4% multiple pregnancies after gonadotrophins versus 6% after CC which can be explained by 372 
the very purpose of ovulation induction in women with anovulation which is to induce  mono-follicular 373 
growth with low doses of gonadotrophins. 9,11  374 
There has traditionally there been reluctance in continuing treatment with CC because of safety issues.9 375 
Of note, direct evidence that cancer risks are increased after six cycles of CC is lacking. 376 
Women treated with gonadotrophins had more miscarriages than women treated with CC. Our study 377 
was not powered to detect a difference in miscarriage rate, hence this finding needs to be confirmed in 378 
future studies.  We found only one second trimester miscarriage in the whole study population, which is 379 
very low and in contrast to the miscarriage rate seen after IVF in a fresh transfer cycle in women with 380 
PCOS.20 This is probably due to the fact that ovulation induction aims folliculogenesis of one follicle 381 
contrast to superovulation in IVF, resulting in a thinner endometrium in ovulation induction. .  382 
The cumulative live birth rate after CC in cycles 7 to 12 is comparable with a previous observational 383 
study.21 Similarly, the cumulative live birth rate after gonadotrophins is in line with a previous 384 





Recent randomized trials and network meta-analyses reported letrozole to be superior to CC in 386 
establishing live births.6,22 We therefore suggest that future research establishes if letrozole is also 387 
effective and safe if women have not conceived within the first six months of treatment. Based on our 388 
current finding that continued treatment with CC is effective, one might hypothesize even higher live 389 
birth rates for continued treatment with letrozole. We therefore suggest to evaluate letrozole in similar 390 
settings.  391 
Our results can be used by couples treated with first line ovulatory drugs who weigh the pros and cons of 392 
switching to gonadotrophins and addition of IUI. CC is known to cause more side effects than 393 
gonadotrophins, while gonadotrophins imply daily injections combined with ultrasound monitoring of 394 
follicular development and are more expensive.23 A recently performed patient preference study on 395 
women with anovulation wishing to conceive showed that just over half of these women chooses 396 
treatment with the least medical interference and lowest burden whereas under 50% prefers a 397 
treatment with the highest success rates regardless of the burden.24 We planned a cost-effectiveness 398 
analyses which will be reported elsewhere.  399 
Our study shows that subfertile women with anovulation who are treated with CC or gonadotrophins 400 
with or without IUI reach acceptable pregnancy rates and low complication rates as they continue to 401 
conceive even until their 12th treatment cycle. This means that switching to IVF after six  failed ovulation 402 
induction cycles is not necessary in contrast to the recommendation of the NICE guideline in unexplained 403 
subfertility.  The choice between these alternatives should therefore be made based on couples 404 
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